CG Oncology (CG Oncology) Operating Cash Flow per Share : $-0.81 (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Operating Cash Flow per Share?

CG Oncology's operating cash flow per share for the three months ended in Mar. 2024 was $-0.55. CG Oncology's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.81.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for CG Oncology's Operating Cash Flow per Share or its related term are showing as below:

CGON's 3-Year OCF Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.45
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

CG Oncology Operating Cash Flow per Share Historical Data

The historical data trend for CG Oncology's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Operating Cash Flow per Share Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Operating Cash Flow per Share

-0.41

-7.97

-10.55

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial			-1.58	-1.84	-	-0.25	-0.55

Competitive Comparison of CG Oncology's Operating Cash Flow per Share

For the Biotechnology subindustry, CG Oncology's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CG Oncology's Price-to-Operating-Cash-Flow falls into.

CG Oncology Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

CG Oncology's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-45.679	/	4.331
	=	-10.55

CG Oncology's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-26.012	/	47.065
	=	-0.55

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.81

CG Oncology Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of CG Oncology's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024